Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded ...

Eli Lilly has reported that its interleukin-13 (IL-13) inhibitor Ebglyss (lebrikizumab-lbkz) showed sustained skin clearance ...

See, LLY stock warrants your attention. Why? Because it offers monopoly-like high margins at a discounted price.

Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...

Eli Lilly and Co. (NYSE: LLY) shares are trading at $813.53 on Thursday morning, inching down 0.01% after a strong run earlier this year.

Eli Lilly and Company (NYSE:LLY) is included among the 10 Best Rising Dividend Stocks to Buy Now. Eli Lilly and Company (NYSE ...

Eli Lilly (LLY) stock and Incyte (INCY) stock in focus as the companies post new late-stage trial data for their hair loss ...

October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...

A new oral medication, Orforglipron, is set to revolutionize weight loss and diabetes management, offering a pill alternative ...